Analysts Set Expectations for ARQT Q1 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Arcutis Biotherapeutics in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao expects that the company will post earnings of $0.08 per share for the quarter. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.16 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q2 2027 earnings at $0.19 EPS, Q3 2027 earnings at $0.25 EPS and Q4 2027 earnings at $0.48 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The company had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.93%.

A number of other equities research analysts also recently weighed in on ARQT. Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Guggenheim lifted their price target on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC boosted their price objective on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley upped their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $35.57.

Arcutis Biotherapeutics Price Performance

NASDAQ ARQT opened at $26.43 on Friday. Arcutis Biotherapeutics has a 12 month low of $13.69 and a 12 month high of $31.77. The firm has a market capitalization of $3.31 billion, a PE ratio of 125.86 and a beta of 1.49. The company’s 50 day simple moving average is $25.97 and its 200 day simple moving average is $24.69. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several hedge funds have recently modified their holdings of the stock. Suvretta Capital Management LLC raised its holdings in shares of Arcutis Biotherapeutics by 14.2% during the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock valued at $347,435,000 after acquiring an additional 1,486,000 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Arcutis Biotherapeutics by 1,228.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock valued at $33,872,000 after acquiring an additional 1,078,546 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Arcutis Biotherapeutics in the 4th quarter worth approximately $26,136,000. State Street Corp boosted its stake in Arcutis Biotherapeutics by 18.2% in the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after purchasing an additional 846,986 shares during the period. Finally, Voloridge Investment Management LLC purchased a new position in Arcutis Biotherapeutics during the 3rd quarter worth approximately $15,711,000.

Insider Buying and Selling at Arcutis Biotherapeutics

In related news, Director Sue-Jean Lin sold 4,946 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.38, for a total transaction of $120,583.48. Following the completion of the sale, the director directly owned 27,567 shares of the company’s stock, valued at $672,083.46. This represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Masaru Matsuda sold 1,230 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $32,127.60. Following the sale, the insider directly owned 126,171 shares of the company’s stock, valued at approximately $3,295,586.52. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,894 shares of company stock valued at $422,044 over the last quarter. Company insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Needham raises price target: Needham & Company raised its price target on ARQT to $40 from $36 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. Benzinga analyst update
• Positive Sentiment: Strong Q2 results and higher guidance: Arcutis reported earnings of $0.11 per share, above estimates of $0.06-$0.09, while revenue of $129.9 million exceeded expectations of $118.9 million. Revenue increased 59% year over year and 23% sequentially, driven by demand for ZORYVE. Management raised 2026 net product sales guidance to $525 million-$540 million and reported positive operating cash flow. Arcutis second-quarter 2026 results
• Positive Sentiment: Additional ZORYVE growth opportunities: The FDA approved ZORYVE cream for plaque psoriasis in children as young as two. The FDA also accepted an application for infants with atopic dermatitis, with a decision expected by February 2027. Results from a Phase 2 vitiligo study are expected in the fourth quarter of 2026. Arcutis business update
• Neutral Sentiment: Routine insider selling: Three executives sold a combined 6,560 shares under pre-arranged Rule 10b5-1 plans to cover tax withholding tied to vested equity awards. Because the sales were administrative and represented less than 1% of each executive’s holdings, they provide limited evidence of bearish conviction. SEC insider trading filing

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.